Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Liver Fibrosis Clear all
Completed Phase 2 Interventional Results available

An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis

NCT03656068
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Fatty Liver, Fibrosis, Liver, Compensated Cirrhosis
Interventions
Nitazoxanide 500mg BID
Drug
Lead sponsor
Pinnacle Clinical Research, PLLC
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Withdrawn Phase 4 Interventional

Rifaximin Versus Lactulose in Renal Failure

NCT00748904
View directory record Official record
Conditions
Liver Cirrhosis, Renal Failure
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

Use of Fenofibrate for Primary Biliary Cirrhosis

NCT00575042
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Gainesville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Not applicable Interventional Results available

Cirrhosis Medical Home

NCT04581369
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
Care Coordinator Intervention for Direct Intervention Group, Care Coordinator Intervention for Standard of Care Group, Caregiver Intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

NCT03517540
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor (LJN452), Cenicriviroc (CVC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Terminated Phase 3 Interventional Results available

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT03028740
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Placebo, Cenicriviroc
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
204
States / cities
Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Completed No phase listed Observational

Usefulness of Cardiopulmonary Exercise Testing for Cardiovascular Risk Estimation and Frailty Assessment in Liver Transplant Candidates

NCT04543825
View directory record Official record
Conditions
Cardiovascular Diseases+Liver Transplantation
Interventions
Cardiopulmonary exercise testing
Device
Lead sponsor
Andres Duarte-Rojo
Other
Eligibility
45 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Sep 24, 2026, 9:05 PM EDT
Not listed Phase 2 Interventional

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

NCT00281502
View directory record Official record
Conditions
Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
Interventions
Rifaximin (drug)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy

NCT00999167
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
HPN-100, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Not applicable Interventional

Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents

NCT04315571
View directory record Official record
Conditions
Hypertension, Portal, Ascites
Interventions
Gore® Viatorr® Endoprosthesis with controlled expansion, Large Volume Paracentesis with albumin infusion
Device · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 24, 2026, 9:05 PM EDT
Completed No phase listed Observational

Shear Wave Elastography

NCT04493346
View directory record Official record
Conditions
Heart Failure, Transplant; Failure, Heart, Decompensated Heart Failure, Fibrosis, Liver, Cirrhosis, Liver
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Composition for Treating Cirrhosis and Liver Cancer (SB-1121)

NCT05178303
View directory record Official record
Conditions
Cirrhosis of the Liver
Interventions
SB-1121(1), SB-1121(2)
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
18 Years to 80 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 24, 2026, 9:05 PM EDT
Recruiting No phase listed Observational

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

NCT06950788
View directory record Official record
Conditions
Cirrhosis, Liver, Diabetes Mellitus Risk, Transplant; Failure, Liver, Transplant-Related Disorder
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 24, 2026, 9:05 PM EDT
Completed No phase listed Observational

Rapid 10-Minute Liver MRI Protocol in Patients With Suspected Hepatocellular Carcinoma

NCT01390194
View directory record Official record
Conditions
Underlying Liver Disease, Hepatitis, Fibrosis of Liver, Cirrhosis With Suspicion of Liver Cancer, Lesion on a Prior Ultrasound, CT or Outside MRI
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 24, 2026, 9:05 PM EDT
Completed No phase listed Observational

Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis

NCT03961516
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis Liver Disease, Pancreatic Steatosis, Hepatic Steatosis
Interventions
Frequently Sampled Oral Glucose Tolerance Test and CGM, MRI Pancreas and Liver
Device · Radiation
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
6 Years to 40 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients

NCT06000748
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Portal Hypertension, Hepatorenal Syndrome, Acute Tubule Necrosis, Prerenal Failure
Interventions
MAP-Target Algorithm
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 24, 2026, 9:05 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

NCT06082843
View directory record Official record
Conditions
Hypertension, Portal, Liver Cirrhosis
Interventions
Placebo, Avenciguat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Pasadena, California • Rialto, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Results available

The SIM-SOF Trial for Hepatitis C

NCT02168361
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pegylated Interferon alfa-2b, Simeprevir, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Center For Hepatitis C, Atlanta, GA
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Adults Evaluating PF-07202954

NCT04857437
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Interventions
PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT02854605
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
GS-9674, Placebo to match GS-9674
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Los Angeles, California • Rialto, California • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 24, 2026, 9:05 PM EDT
Not listed Early Phase 1 Interventional

Body Composition Changes After TIPS and Associated Clinical Outcomes

NCT05420753
View directory record Official record
Conditions
Cirrhosis, Liver, Sarcopenia
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Not applicable Interventional

Use of EL-FIT App to Promote Physical Activity

NCT04604860
View directory record Official record
Conditions
End Stage Liver DIsease, Cirrhosis, Liver
Interventions
Fitness intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Completed No phase listed Observational

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

NCT01161953
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Genetic Analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Not applicable Interventional

Ischemic Preconditioning of Liver in Cadaver Donors

NCT00245830
View directory record Official record
Conditions
Liver Cirrhosis, Liver Disease
Interventions
Ischemic Preconditioning
Procedure
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Sep 24, 2026, 9:05 PM EDT